SCHEMBL24744900

SCHEMBL24744900

COC(=O)c1c(F)ccc2c1nc(C)n2CC(=O)OC(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.38
▸ KDM4E B2RXH2 3/20 0.38
▸ CACNA1B Q00975 1/20 0.37
▸ MAPT P10636 4/20 0.37
▸ LMNA P02545 1/20 0.37
▸ HK1 P19367 1/20 0.37
▸ HKDC1 Q2TB90 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ PTGER4 P35408 2/20 0.34
▸ GAA P10253 1/20 0.34
▸ TLR7 Q9NYK1 1/20 0.34
▸ PLA2G7 Q13093 1/20 0.34
▸ JAK2 O60674 1/20 0.33
▸ JAK1 P23458 1/20 0.33
▸ JAK3 P52333 1/20 0.33
▸ PKN1 Q16512 1/20 0.32
▸ PKN2 Q16513 1/20 0.32
▸ NPC1 O15118 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24745490 0.89 ALDH1A1 (0.40) ALDH1A1KDM4ECACNA1BMAPTLMNA
SCHEMBL30938930 0.82 TLR7 (0.36) ALDH1A1KDM4ECACNA1BMAPTLMNA
SCHEMBL29893726 0.80 PKN1 (0.47) ALDH1A1KDM4EMAPTLMNAPTGER4
SCHEMBL24744762 0.80 PKN1 (0.47) ALDH1A1KDM4EMAPTLMNAPTGER4
SCHEMBL24745467 0.78 ALDH1A1 (0.37) ALDH1A1KDM4ECACNA1BMAPTLMNA
SCHEMBL24745532 0.76 DCTPP1 (0.38) ALDH1A1KDM4ECACNA1BMAPTTLR7
SCHEMBL30938924 0.75 KDM4E (0.37) ALDH1A1KDM4ECACNA1BHSD17B10PTGER4
SCHEMBL24745449 0.75 CACNA1B (0.40) ALDH1A1KDM4ECACNA1BMAPTPTGER4
SCHEMBL24745728 0.74 ALDH1A1 (0.37) ALDH1A1KDM4ECACNA1BMAPTGAA
SCHEMBL24744896 0.73 KDM4E (0.36) ALDH1A1KDM4ECACNA1BMAPTPTGER4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240294499-A1 TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN CAPTOR THERAPEUTICS S.A. (PL) 2024-09-05 — — US disclosed
CN-117957218-A Targeted protein degradation using bifunctional compounds that bind to ubiquitin ligases and target MCL-1 proteins 凯普托尔治疗学股份有限公司 2024-04-30 — — CN disclosed
WO-2022253713-A1 TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN CAPTOR THERAPEUTICS S.A. (PL) 2022-12-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240294499-A1 TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN MCL1, MDM2, XIAP ALDH1A1 956/4885KDM4E 1943/4885CACNA1B 4588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback